Halloween may be at the end of the month, but biotech investors have already seen their fair share of scares so far in October. In this video, health care analyst David Williamson goes over the rash of dilutive capital raises hitting the sector, including three announced just Wednesday night.
Despite dilution being a way of life for development-stage biotechs, investors are still attracted to industry by the allure of substantial short term gains. But there is a better approach to building long-term wealth and retiring well. In our free report "3 Stocks That Will Help You Retire Rich," we reveal some stocks that could help you as well as some winning wealth-building strategies. Click here to keep reading.